Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.

Completed · Phase 3 · Has a placebo group

Conditions studied: Heart Failure With Preserved Ejection Fraction

In brief

This is an international, multicentre, parallel-group, event-driven, randomised, double-blind, placebo-controlled study in HFpEF patients, evaluating the effect of dapagliflozin 10 mg versus placebo, given once daily in addition to background regional standard of care therapy, including treatments to control co-morbidities, in reducing the composite of CV death or heart failure events.

Key facts

Study ID: NCT03619213
Run by: AstraZeneca
People needed: 6263
Starts: 2018-08-27
Expected to finish: 2022-03-27
Last updated by the study team: 2023-07-11

Who can join

Age: 40 and older, up to 130. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Provision of signed informed consent prior to any study specific procedures.
Male or female patients age ≥40 years.
Documented diagnosis of symptomatic heart failure (NYHA class II-IV) at enrolment, and a medical history of typical symptoms/signs of heart failure ≥6 weeks before enrolment with at least intermittent need for diuretic treatment.
Left Ventricular Ejection Fraction (LVEF) >40% and evidence of structural heart disease (i.e. left ventricular hypertrophy or left atrial enlargement ) documented by the most recent echocardiogram, and/or cardiac MR within the last 12 months prior to enrolment. For patients with prior acute cardiac events or procedures that may reduce LVEF, e.g. as defined in exclusion criterion 6, qualifying cardiac imaging assessment at least 12 weeks following the procedure/event is required.
Elevated NT-pro BNP levels.
Both ambulatory and hospitalised patients may be enrolled and randomised. Patients currently hospitalised for HF, must be off intravenous HF medications for at least 24 before randomisation.
Further details regarding inclusion criteria 4-6 may apply.

You may not qualify if…

Receiving therapy with an SGLT2 inhibitor within 4 weeks prior to randomisation or previous intolerance to an SGLT2 inhibitor.
Type 1 diabetes mellitus (T1D).
eGFR <25 mL/min/1.73 m2 (CKD-EPI formula) at Visit 1.
Systolic blood pressure (BP) <95 mmHg on 2 consecutive measurements at 5-minute intervals, at Visit 1 or at Visit 2.
Systolic BP≥160 mmHg if not on treatment with ≥3 blood pressure lowering medications or ≥180 mmHg irrespective of treatments, on 2 consecutive measurements at 5-minute intervals, at Visit 1 or at Visit 2.
MI, unstable angina, coronary revascularization (percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)), ablation of atrial flutter/fibrillation, valve repair/replacement within 12 weeks prior to enrolment. Before enrolment, these patients must have their qualifying echocardiography and/or cardiac MRI examination at least 12 weeks after the event.
Planned coronary revascularization, ablation of atrial flutter/fibrillation and valve repair/replacement.
Stroke or transient ischemic attack (TIA) within 12 weeks prior to enrolment.
Probable alternative or concomitant diagnoses which in the opinion of the investigator could account for the patient's HF symptoms and signs (e.g. anaemia, hypothyroidism).
Body mass index >50 kg/m2.
Further exclusion criteria may apply

Where it is running

Research Site — Mobile, Alabama, United States
Research Site — Sheffield, Alabama, United States
Research Site — Tucson, Arizona, United States
Research Site — Little Rock, Arkansas, United States
Research Site — Beverly Hills, California, United States
Research Site — Loma Linda, California, United States
Research Site — Los Angeles, California, United States
Research Site — Stamford, Connecticut, United States
Research Site — Clearwater, Florida, United States
Research Site — Miami, Florida, United States
Research Site — Naples, Florida, United States
Research Site — Ocala, Florida, United States
Research Site — Ormond Beach, Florida, United States
Research Site — Port Charlotte, Florida, United States
Research Site — Saint Augustine, Florida, United States
Research Site — Atlanta, Georgia, United States
Research Site — Chicago, Illinois, United States
Research Site — Chicago, Illinois, United States
Research Site — Gurnee, Illinois, United States
Research Site — Anderson, Indiana, United States
Research Site — Munster, Indiana, United States
Research Site — Louisville, Kentucky, United States
Research Site — Hammond, Louisiana, United States
Research Site — Houma, Louisiana, United States
Research Site — Fairhope, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.